Needham & Company Downgrades Hyperion Therapeutics (HPTX) to Hold Amid Takeover Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cantor Fitzgerald Downgrades Hyperion Therapeutics (HPTX) to Hold Amid Takeover Deal
March 31, 2015 6:35 AM EDTCantor Fitzgerald downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Buy to Hold with a price target of $46.00 (from $35.00) following the takeover deal from Horizon.
"We are not expecting a competing bidder at this time since Hyperion management indicated that it utilized advisers and ran an... More
Roth Capital Downgrades Hyperion Therapeutics (HPTX) to Neutral
March 30, 2015 12:50 PM EDTRoth Capital downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $42.74 yesterday.
... MoreWedbush Downgrades Hyperion Therapeutics (HPTX) to Neutral
March 30, 2015 12:49 PM EDTWedbush downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Outperform to Neutral.
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $42.74 yesterday.
... MoreHorizon Pharma (HZNP) PT Raised to $35 at Guggenheim Following Hyperion (HPTX) Deal
March 30, 2015 12:28 PM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Horizon Pharma (NASDAQ: HZNP) to $35.00 (from $31.00) following today's acquisition on Hyperion (NASDAQ: HPTX).
"This was another good strategic and financial deal,... More
Brean Capital Downgrades Hyperion Therapeutics (HPTX) to Hold
March 30, 2015 11:07 AM EDTBrean Capital downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Buy to Hold.
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $42.74 yesterday.
... MoreHorizon Pharma (HZNP) to Acquire Hyperion Therapeutics (HPTX) in $1.1B Deal
March 30, 2015 6:10 AM EDTHorizon Pharma (Nasdaq: HZNP) and Hyperion Therapeutics, Inc. (Nasdaq: HPTX) announced they have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis. The per share consideration represents a premium of approximately 35 percent to Hyperion's volume weighted average price for the trailing 60-days. The proposed transaction has been unanimously approved by both companies' boards of directors.
"The Hyperion acquisition will expand and diversify... More
